



## Artificial Disc Replacement, Cervical Clinical Coverage Criteria

### Overview

Artificial disc replacement, also known as disc arthroplasty, refers to the replacement of a symptomatic, damaged or degenerated intervertebral disc in the spine with an artificial disc. Cervical artificial disc replacement (CADR) has been proposed as an alternative to anterior cervical discectomy and fusion (ACDF) for the treatment of degenerative conditions of the cervical spine. The major potential benefits of CADR over ACDF are preservation of segmental motion and reduction in adjacent segment disease. Clinical trials, in general, have established CADR as a safe and effective alternative to ACDF in the treatment of cervical degenerative disease at 1 or 2 contiguous levels.

### Policy

This Policy applies to the following Fallon Health products:

- Commercial
- Medicare Advantage
- MassHealth ACO
- NaviCare
- PACE

Fallon Health uses guidance from the Centers for Medicare and Medicaid Services (CMS) for coverage determinations for Medicare Advantage, NaviCare and PACE plan members. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs) and guidance in the Medicare manuals are the basis for coverage determinations. When there is no NCD, LCD or manual guidance, Fallon Health Clinical Coverage Criteria are used for coverage determinations.

Medicare does not have a National Coverage Determination (NCD) for cervical artificial disc replacement. National Government Services, Inc. does not have a Local Coverage Determination (LCD) or Local Coverage Article (LCA) for cervical artificial disc replacement at this time.

Prior authorization is required. The artificial disc must be approved by FDA and used in accordance with FDA-approved Labeling (Instructions for Use).

Fallon Health covers cervical artificial disc replacement when all of the following criteria are met:

1. The patient has intractable cervical radicular pain or myelopathy
  - a. which has failed at least 6 weeks of conservative non-operative treatment, including active pain management program or protocol, under the direction of a physician, with pharmacotherapy that addresses neuropathic pain and other pain sources AND physical therapy; OR
  - b. if the patient has severe or rapidly progressive symptoms of nerve root or spinal cord compression requiring hospitalization or immediate surgical treatment.

2. Degeneration is documented by magnetic resonance imaging (MRI), computed tomography (CT), or myelography.
3. Cervical degenerative disc disease is from C3-C7.

Simultaneous cervical artificial intervertebral disc implantation at a second contiguous level is covered if the above criteria are met for each disc level, and the device is FDA-approved for 2 levels (i.e., Mobi-C, Prestige LP).

Subsequent cervical artificial intervertebral disc implantation at an adjacent level is covered when all of the following are met:

1. Criteria 1 to 3 above are met; and
2. The device is FDA-approved for 2 levels; and
3. Clinical documentation that the initial cervical artificial intervertebral disc implantation is fully healed.

Revision or removal of a cervical artificial disc(s) is covered when medically necessary. Prior authorization is required.

Requests for removal of a cervical artificial disc(s) (CPT 22864 +/- 0095T) should include a request for fusion.

## Exclusions

- Cervical artificial disc replacement adjacent to a previous cervical fusion is not covered.
- Cervical artificial disc replacement at three or more levels is considered experimental and is not covered.

## Coding

The following codes are included below for informational purposes only; inclusion of a code does not constitute or imply coverage or reimbursement.

Code	Description
22856	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophylectomy for nerve root or spinal cord decompression and microdissection), single interspace, cervical
22858	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophylectomy for nerve root or spinal cord decompression and microdissection); second level, cervical (List separately in addition to code for primary procedure)
22861	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical
22864	Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical
0095T	Removal of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical
0098T	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical

## References

1. Bono CM, Ghiselli G, Gilbert TJ, et al. An evidence-based clinical guideline for the diagnosis and treatment of cervical radiculopathy from degenerative disorders. *Spine J.* 2011; 11(1):64-72.
2. Zigler JE, Delamarter R, Murrey D et al. ProDisc-C and anterior cervical discectomy and fusion as surgical treatment for single-level cervical symptomatic degenerative disc disease:

- five-year results of a Food and Drug Administration study. *Spine (Phila Pa 1976)*. 2013; 38(3):203-9.
3. Delamarter RB, Zigler J. Five-year Reoperation Rates, Cervical Total Disc Replacement versus Fusion, Results of a Prospective Randomized Clinical Trial. *Spine (Phila Pa 1976)*. 2013; 38(9):711-7.
  4. Zhang HX, Shao YD, Chen Y, et al. A prospective, randomised, controlled multicentre study comparing cervical disc replacement with anterior cervical decompression and fusion. *Int Orthop*. Dec 2014;38(12):2533-2541.
  5. Vaccaro A, Beutler W, Peppelman W, et al. Clinical outcomes with selectively constrained SECURE-C cervical disc arthroplasty: two-year results from a prospective, randomized, controlled, multicenter investigational device exemption study. *Spine (Phila Pa 1976)*. Dec 15 2013;38(26):2227-2239.
  6. Phillips FM, Lee JY, Geisler FH, et al. A prospective, randomized, controlled clinical investigation comparing PCM cervical disc arthroplasty with anterior cervical discectomy and fusion. 2-year results from the US FDA IDE clinical trial. *Spine (Phila Pa 1976)*. 2013 Jul 1;38(15):907-18.
  7. Phillips FM, Geisler FH, Gilder KM, et al. Long-term Outcomes of the US FDA IDE Prospective, Randomized Controlled Clinical Trial Comparing PCM Cervical Disc Arthroplasty with Anterior Cervical Discectomy and Fusion. *Spine (Phila Pa 1976)*. 2015 May 15;40(10):674-83.
  8. Zhong ZM, Zhu SY, Zhuang JS, et al. Reoperation After Cervical Disc Arthroplasty Versus Anterior Cervical Discectomy and Fusion: A Meta-analysis. *Clin Orthop Relat Res*. 2016 May;474(5):1307-16.
  9. Zhu Y, Zhang B, Liu H, et al. Cervical Disc Arthroplasty Versus Anterior Cervical Discectomy and Fusion for Incidence of Symptomatic Adjacent Segment Disease: A Meta-Analysis of Prospective Randomized Controlled Trials. *Spine (Phila Pa 1976)*. 2016 Oct 1;41(19):1493-502.
  10. Reinas R, Kitumba D, Pereira L., et al. Multilevel cervical arthroplasty-clinical and radiological outcomes. J. Huppert, J. Beaurain, J. P. Steib, P. et al., Comparison between single- and multi-level patients: clinical and radiological outcomes 2 years after cervical disc replacement. *Eur Spine J*. 2011 Sep; 20(9): 1417–1426. *J Spine Surg*. 2020 Mar;6(1):233-242.
  11. Wang QL, Tu ZM, Hu P, et al., Long-term Results Comparing Cervical Disc Arthroplasty to Anterior Cervical Discectomy and Fusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Orthop Surg*. 2020 Feb;12(1):16-30.
  12. Niedzielak TR, Ameri BJ, Emerson B, et al., Trends in cervical disc arthroplasty and revisions in the Medicare database. *J Spine Surg*. 2018 Sep;4(3):522-528. doi: 10.21037/jss.2018.09.04.
  13. Skovrlj B, Lee DH, Caridi JM, Cho SK. Reoperations Following Cervical Disc Replacement. *Asian Spine J*. 2015 Jun;9(3):471-82.
  14. Davis RJ, Nunley PD, Kim KD, et al. Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: A prospective, randomized, controlled multicenter clinical trial with 4-year follow-up results. *J Neurosurg Spine*. 2015; 22(1):15-25.
  15. Cheng L, Nie L, Zhang L, et al. Fusion versus Bryan cervical disc in two-level cervical disc disease: A prospective, randomised study. *Int Orthop*. 2009; 33(5):1347-51.
  16. Matz PG, Ryken TC, Groff MW, et al. Techniques for anterior cervical decompression for radiculopathy. *J Neurosurg Spine*. 2009; 11(2):183-197.
  17. Singh K, Phillips FM, Park DK, et al. Factors affecting reoperations after anterior cervical discectomy and fusion within and outside of a Federal Drug Administration investigational device exemption cervical disc replacement trial. *Spine J*. 2012 May;12(5):372-8.
  18. Turel MK, Kerolus MG, Adogwa O, Traynelis VC. Cervical arthroplasty: what does the labeling say? *Neurosurg Focus*. 2017 Feb;42(2):E2.
  19. Badve SA, Kurra S, Nunley PD, Lavelle WF. The Mobi-C® cervical disc and other devices for two-level disc replacement: overview of its safety and efficacy. *Expert Rev Med Devices*. 2019 Apr;16(4):307-315.
  20. Rhee J, Van Alstyne EM, Skelly, AC. Cervical artificial disc replacement (C-ADR): global perspectives on use and trends. *Evid Based Spine Care J*. 2012 Feb; 3(Suppl 1): 53–58.

21. Lu H, Peng L. Efficacy and safety of Mobi-C cervical artificial disc versus anterior discectomy and fusion in patients with symptomatic degenerative disc disease: A meta-analysis. *Medicine (Baltimore)*. 2017 Dec;96(49):e8504.
22. Findlay C, Ayis S, Demetriades AK. Total disc replacement versus anterior cervical discectomy and fusion: a systematic review with meta-analysis of data from a total of 3160 patients across 14 randomized controlled trials with both short- and medium- to long-term outcomes. *Bone Joint J*. 2018 Aug;100-B(8):991-1001.
23. Radcliff K, Coric D, Albert T. Five-year clinical results of cervical total disc replacement compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial. *J Neurosurg Spine*. 2016 Aug;25(2):213-24.
24. Gornet MF, Burkus JK, Shaffrey ME. Cervical disc arthroplasty: 10-year outcomes of the Prestige LP cervical disc at a single level. *J Neurosurg Spine*. 2019 May 10;31(3):317-325.
25. Gornet MF, Lanman TH, Burkus JK. Two-level cervical disc arthroplasty versus anterior cervical discectomy and fusion: 10-year outcomes of a prospective, randomized investigational device exemption clinical trial. *J Neurosurg Spine*. 2019 Jun 21:1-11.
26. Zhang Y, Lv N, He F, et al. Comparison of cervical disc arthroplasty and anterior cervical discectomy and fusion for the treatment of cervical disc degenerative diseases on the basis of more than 60 months of follow-up: a systematic review and meta-analysis. *BMC Neurol*. 2020 Apr 20;20(1):143.
27. Badhiwala JH, Platt A, Witiw CD, Traynelis VC. Cervical disc arthroplasty versus anterior cervical discectomy and fusion: a meta-analysis of rates of adjacent-level surgery to 7-year follow-up. *J Spine Surg*. 2020 Mar;6(1):217-232.
28. Bhashyam N, De la Garza Ramos R, Nakhla J, et al. Thirty-day readmission and reoperation rates after single-level anterior cervical discectomy and fusion versus those after cervical disc replacement. *Neurosurg Focus*. 2017 Feb;42(2):E6.
29. Gornet MF, Lanman T2, Burkus JK, et al. One-Level Versus 2-Level Treatment with Cervical Disc Arthroplasty or Fusion: Outcomes Up to 7 Years. *Int J Spine Surg*. 2019 Dec 31;13(6):551-560.
30. Health Quality Ontario. Cervical artificial disc replacement versus fusion for cervical degenerative disc disease: a health technology assessment. *Ont Health Technol Assess*. 2019 Feb;19(3): 1–223.

## Policy history

Origination date: 05/01/2014  
 Approval(s): Technology Assessment Committee 12/18/2013 (Adopted Interqual Criteria). 01/28/2015 (annual review), 01/27/2016 (annual review), 01/25/2017 (annual review), 01/24/2018 (annual review) 1/23/2019 (annual review); 05/27/2020 (Adopted Fallon Health criteria).

06/15/2021 (Added clarifying language related to Medicare Advantage, NaviCare and PACE under policy section).

*Not all services mentioned in this policy are covered for all products or employer groups. Coverage is based upon the terms of a member's particular benefit plan which may contain its own specific provisions for coverage and exclusions regardless of medical necessity. Please consult the product's Evidence of Coverage for exclusions or other benefit limitations applicable to this service or supply. If there is any discrepancy between this policy and a member's benefit plan, the provisions of the benefit plan will govern. However, applicable state mandates take precedence with respect to fully-insured plans and self-funded non-ERISA (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, federal mandates will apply to all plans. For Medicare and Medicaid members, this policy will apply unless Medicare and Medicaid policies extend coverage beyond this policy.*